Evolution of the Average Target: Valneva SE Pref.

Evolution of the Target Price: Valneva SE Pref.

Changes in Analyst Recommendations: Valneva SE Pref.

17ad11c6ba33555eb09f5820bd.WUc4RyvpTfgw8kDJviXRR6--G0Etcp2JgzfhHhK4NRA.MBIVPmOtG7FSn3aW_W2TNO75Ty9qGe7tzEeYUl7TfVYoFQ0dQt8mlnGBBQ~dfdbcb1755b061ab78737c5080491766
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
25-09-03 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
25-08-26 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
25-08-26 Valneva: Stifel adjusts target price Zonebourse
25-08-12 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
25-07-14 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
24-08-13 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24-06-24 Valneva rises after Canadian approval for its chikungunya vaccine RE
24-02-05 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24-01-02 Valneva: Oddo BHF remains positive Zonebourse
23-11-10 HC Wainwright Adjusts Price Target on Valneva SE to $26 From $22, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.2%
+7.17%
+10.48%
+38.69%
+46.5%
+9.89%
-16.13%
+3%
+7.81%
Average +13.51%
Weighted average by Cap. +16.23%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.179EUR
Average target price
5.233EUR
Spread / Average Target
+140.17%
High Price Target
7.500EUR
Spread / Highest target
+244.19%
Low Price Target
2.100EUR
Spread / Lowest Target
-3.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
HC Wainwright
Kepler Cheuvreux
Guggenheim
Jefferies & Co.
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.179EUR
Average target price
5.233EUR
Spread / Average Target
+140.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. VLAP Stock
  5. Consensus Valneva SE Pref.